Navigation Links
Frequent inaccuracies in testosterone testing lead to call for standardization

Chevy Chase, MDThe use of testosterone assays for patient care and research is on the rise as new research links testosterone to a variety of diseases and conditions. Although the assays are heavily used, discrepancies and inaccuracies in measurements resulting from the various assays are widespread. Seeking to address this critical health issue, a multidisciplinary group of experts convened by The Endocrine Society and the US Centers for Disease Control and Prevention just issued recommendations for improving and standardizing testosterone testing in a consensus statement to be published in the October 2010 issue of The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

Testosterone assays are tests that measure testosterone levels which, in turn, are used to diagnose and treat patients with a number of disorders. These disorders may include: testicular or pituitary diseases in men potentially leading to erectile dysfunction and decreased sexual drive; polycystic ovarian syndrome which may cause menstrual disturbances and infertility in women; and early or late pubertal development in children.

"The development of this consensus statement has been a collaborative effort among key stakeholders including professional societies, laboratories and regulatory agencies," said William Rosner, MD, a lead author of the consensus statement and a member of The Endocrine Society. "Not only does this entire group benefit from better assays, but all bear some responsibility in working to improve accuracy."

Aimed at improving the quality of research, patient care and public health through broad implementation of standardized testosterone measurements that are accurate, reliable and comparable over time, the consensus statement recommends the following:

  • All stakeholders should acknowledge the importance of testosterone assay standardization and work closely with the CDC to formulate plans to implement accuracy-based, calibrated testing across the community of assay providers and users;
  • The expert scientific and medical communities should work to:

    • define performance criteria that cover the full range of expected values, from children to adult males and females;
    • define reference intervals for testosterone in adults and children of both sexes; and
    • develop guidelines and protocols to ensure uniform patient preparation and handling of samples before they are assayed.

  • Third-party payers and health care organizations should promote the use of and enable payment for assays that have been standardized through the above mentioned efforts;
  • Funding entities, journals and others involved in research should support the standardization of assays; and
  • Manufacturers and laboratories should continue to develop new methodological approaches ensuring the sensitive, specific, accurate and cost-effective measurement of testosterone.

"The recommendations in this consensus statement emphasize the need for the research, medical and industry communities to each play their part in improving testosterone assays," said Rosner. "High quality testosterone testing will not only provide for better patient care outcomes but will rein in the cost of health care as they will lessen the need for frequent retesting."

The consensus statement has been endorsed by the following organizations:

  • American Association for Clinical Chemistry
  • American Association of Clinical Endocrinologists
  • Androgen Excess/PCOS Society
  • American Society for Bone and Mineral Research
  • American Society for Reproductive Medicine
  • American Urological Association
  • Association of Public Health Laboratories
  • The Endocrine Society
  • Laboratory Corporation of America
  • North American Menopause Society
  • Pediatric Endocrine Society (formerly known as Lawson Wilkins Pediatric Endocrine Society)

The Coalition for Quality Testing, comprising most of the groups listed above and other interested organizations, has been formed to address the technical aspects of reference intervals and performance criteria; to develop guidelines and protocols; and to educate third-party payers, funding entities, journals and other relevant stakeholders.

The statement, "Toward Excellence in Testosterone Testing; A Consensus Statement," will appear in the October 2010 issue of JCEM.


Contact: Aaron Lohr
The Endocrine Society

Related medicine news :

1. News brief: Benefit of HPV Vaccination, Frequent Screening for Women over 41 is Likely to be Low
2. MSU researcher links potentially deadly infection, frequent cow exposure
3. Do men with early prostate cancer commit suicide more frequently?
4. The most frequent error in medicine
5. Immigrants with disabilities more frequently employed than US-born persons with disabilities
6. Evidence-based medicine theory can be applied to frequent flying says US professor
7. Botox reduces wrinkles even in less frequent doses
8. Frequent Doctor Visits Help Diabetics Control Blood Pressure
9. Frequent Urination at Night Linked to Raised Death Risk
10. Anxiety/panic disorder most frequent disabling comorbid disorder in TS patients, study finds
11. Adverse childhood experiences linked to frequent headache in adults
Post Your Comments:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... non-traumatic limb amputations in the United States. Podiatrists are well aware that psychology-based ... adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... 2015 , ... TCS Healthcare Technologies (TCS), a leading provider ... is pleased to announce that VIP Care Services, a Caprock Health Group affiliate ... Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY Complete ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... BOSTON , December 1, 2015 Russia ... phase III clinical trials. 70% of new drugs registered in ... trials in Russia . --> Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: